story of the week
Metformin Reduces HCC Risk in Patients With Diabetes and Chronic Hepatitis C After Successful Antiviral Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
J. Hepatol. 2023 Feb 01;78(2)281-292, PC Tsai, HT Kuo, CH Hung, KC Tseng, HC Lai, CY Peng, JH Wang, JJ Chen, PL Lee, RN Chien, CC Yang, GH Lo, JH Kao, CJ Liu, CH Liu, SL Yan, MJ Bair, CY Lin, WW Su, CH Chu, CJ Chen, SY Tung, CM Tai, CW Lin, CC Lo, PN Cheng, YC Chiu, CC Wang, JS Cheng, WL Tsai, HC Lin, YH Huang, ML Yeh, CF Huang, MH Hsieh, JF Huang, CY Dai, WL Chung, CY Chen, ML YuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.